NCT03646552View on ClinicalTrials.gov

A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

THX-110

"Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days."

Trial Locations (1)

6789140

RECRUITING

Assuta HaShalom, Tel Aviv

Sponsors

Lead Sponsor

SciSparc
All Listed Sponsors
lead

SciSparc

INDUSTRY

NCT03646552 - A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter